Menno T Pruijm
Centre Hospitalier Universitaire Vaudois1 paperORCID 0000-0003-1027-1851OpenAlex
Papers
Nature MedicineHuman trial
Semaglutide curbs kidney vascular resistance and fibrosis
In 106 people with diabetes and kidney disease, 52 weeks of semaglutide reduced vascular resistance and stabilized markers of fibrosis compared to…In 106 people with diabetes and kidney disease, 52 weeks of semaglutide reduced vascular resistance and stabilized markers of fibrosis compared to placebo.